Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0UF0N
|
||||
Former ID |
DIB001459
|
||||
Drug Name |
ACP-319
|
||||
Indication | Chronic lymphocytic leukaemia [ICD10:C91] | Phase 1/2 | [549565] | ||
Company |
Acerta pharma
|
||||
Target and Pathway | |||||
Target(s) | Tyrosine-protein kinase BTK | Target Info | Inhibitor | [543527] | |
PANTHER Pathway | B cell activation | ||||
PathWhiz Pathway | Fc Epsilon Receptor I Signaling in Mast Cells | ||||
Reactome | MyD88:Mal cascade initiated on plasma membrane | ||||
Regulation of actin dynamics for phagocytic cup formation | |||||
DAP12 signaling | |||||
FCERI mediated Ca+2 mobilization | |||||
MyD88 deficiency (TLR2/4) | |||||
IRAK4 deficiency (TLR2/4) | |||||
RHO GTPases Activate WASPs and WAVEs | |||||
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers | |||||
References |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.